FDA Panel Backs 6 Experimental Peptides for Compounding as Scientists Warn of Liver Damage

A July FDA advisory panel voted to ease restrictions on six unapproved peptides — including BPC 157, TB 500 and MOTS c — by recommending they be added to the 503A bulks list for compounding pharmacies. The vote followed Health Secretary Robert F.